European Commission approves Novartis' Itvisma
Analysis based on 7 articles · First reported Jul 02, 2026 · Last updated Jul 03, 2026
The approval of Itvisma by the International — European Commission is expected to positively impact Novartis's stock price and market position in the gene therapy sector. It provides a new treatment option for a broad patient population with spinal muscular atrophy in the European Union, potentially increasing Novartis's revenue and market share.
The International — European Commission has approved Novartis's Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens, and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. This makes Itvisma the first and only gene replacement therapy approved for this broad SMA population in the European Union. The therapy is a one-time fixed dose that addresses the genetic root cause of SMA by replacing the SMN1 gene, aiming to improve motor function. The approval is based on data from the STEER, STRENGTH, and STRONG studies, which demonstrated statistically significant and clinically meaningful benefits. Novartis holds exclusive worldwide licenses for AAV9 gene replacement therapy for SMA from Nationwide Children s Hospital, REGENXBIO, and Genethon.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard